On the stock market since 2021, it operates in the world of health and science. It has 13 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 56% below its peak. The market has trimmed its expectations for the company.
Sales run at $2.0M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 6 buys and 5 sells. Management buying with its own money is usually read as a good sign.
A loss of $8.2M against $2.0M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, NTRB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NTRB is a high-risk stock — not yet profitable, and its future rides on its product catching on.